0000874716-24-000017.txt : 20240209 0000874716-24-000017.hdr.sgml : 20240209 20240209170355 ACCESSION NUMBER: 0000874716-24-000017 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240208 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FENNELL GEORGE CENTRAL INDEX KEY: 0001521861 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19271 FILM NUMBER: 24615986 MAIL ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE CENTRAL INDEX KEY: 0000874716 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 010393723 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 BUSINESS PHONE: 2075560300 MAIL ADDRESS: STREET 1: ONE IDEXX DRIVE CITY: WESTBROOK STATE: ME ZIP: 04092-2041 FORMER COMPANY: FORMER CONFORMED NAME: IDEXX CORP / DE DATE OF NAME CHANGE: 19600201 4 1 wk-form4_1707516212.xml FORM 4 X0508 4 2024-02-08 0 0000874716 IDEXX LABORATORIES INC /DE IDXX 0001521861 FENNELL GEORGE ONE IDEXX DRIVE WESTBROOK ME 04092 0 1 0 0 SVP, Chief Revenue Officer 0 Common Stock 2024-02-08 4 M 0 1612 62 A 6712 D Common Stock 2024-02-08 4 M 0 8198 62 A 14910 D Common Stock 2024-02-08 4 S 0 1209 572.1356 D 13701 D Common Stock 2024-02-08 4 S 0 2279 572.7797 D 11422 D Common Stock 2024-02-08 4 S 0 1125 573.9761 D 10297 D Common Stock 2024-02-08 4 S 0 3173 575.0167 D 7124 D Common Stock 2024-02-08 4 S 0 412 575.8027 D 6712 D Incentive Stock Option (right-to-buy) 62 2024-02-08 4 M 0 1612 0 D 2024-02-13 Common Stock 1612 0 D Non-Qualified Stock Option (right-to-buy) 62 2024-02-08 4 M 0 8198 0 D 2024-02-13 Common Stock 8198 0 D Represents the weighted average price of the shares sold ranging from a low of $571.50 to a high of $572.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Represents the weighted average price of the shares sold ranging from a low of $572.525 to a high of $573.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Represents the weighted average price of the shares sold ranging from a low of $573.58 to a high of $574.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Represents the weighted average price of the shares sold ranging from a low of $574.625 to a high of $575.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Represents the weighted average price of the shares sold ranging from a low of $575.78 to a high of $575.845 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Grant of option to buy 806 shares of Issuer common stock that vested in one installment on February 14, 2019, without giving effect to a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the 'Stock Split'). The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. Grant of option to buy 4,099 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2015, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split. /s/ Lily J. Lu, Attorney-in-Fact for George Fennell 2024-02-09